Daraxonrasib Shrinks Tumors in 30% of 136 Lung Cancer Patients After Early Trial
Updated
Updated · abcnews.com · Sep 3
Daraxonrasib Shrinks Tumors in 30% of 136 Lung Cancer Patients After Early Trial
3 articles · Updated · abcnews.com · Sep 3
Summary
An early-phase trial in 136 patients with non-small cell lung cancer found daraxonrasib reduced tumor burden in more than 30% of participants whose disease had resisted prior therapies.
Response rates rose with dose—31% in the low-dose group, 34% in the mid-dose group and 37% in the high-dose group—suggesting activity against RAS-driven tumors.
Safety remains a hurdle: almost all patients reported side effects, and 54% had severe events including rash, diarrhea, nausea, vomiting, pneumonia and low blood counts.
The pill was approved by the FDA last week for metastatic pancreatic adenocarcinoma after a 500-patient late-stage trial showed median overall survival of more than 13 months versus 6.7 months on standard chemotherapy.
For lung cancer—the leading cause of cancer death, with about 230,000 U.S. diagnoses and 125,000 expected deaths this year—the FDA would likely require larger late-stage trials before considering approval.